Dr. Villanueva Takes Aim at NRAS Mutant Melanoma
When Dr. Villanueva began her work in melanoma, some 15 years ago, it was the perfect scientific challenge. How could a disease be so aggressive – and still be such a mystery?
Then things got personal.
Coronavirus: What People with Cancer Should Know
Coronaviruses are a large family of viruses that are common in people and many different species of animals. CDC is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China and has now been detected in the United States and many other countries.
Harnessing Artificial Intelligence to Detect Melanoma Earlier
2 March 2020 In Science
As an internist, Dr. Joann Elmore was taught to ask questions. Those questions led her to spend much of her career in breast cancer research where she found extensive variability among radiologists’ interpretation of mammograms. “Radiology data is subjective, just like art. You’re being asked to classify visual data,” Elmore says.
Combination Therapy: Why Timing Might Be Everything
By Rachel Fischer, Ph.D., Senior Associate, Scientific Program and Grants Administration | 13 February 2020 In Science
About half of all melanomas have a mutated BRAF gene. This mutated gene makes an altered BRAF protein, which leads to the uncontrolled growth of melanoma cells. Drugs targeting these altered BRAF proteins, such as Vemurafenib and Dabrafenib have been approved for the treatment of BRAF+ melanoma.
Clinical Trials to Watch: Intralesional Therapies for Melanoma
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 8 February 2020 In Science, Treatment
To an outsider, the number of new treatment options for melanoma may seem to be moving at a breakneck pace. Checkpoint immunotherapy and BRAF/MEK inhibitors have greatly improved outcomes for many late-stage melanoma patients, with over 50% of patients on combination ipilimumab/nivolumab still alive after 5 years.
Stage 4 Melanoma, a Vaccine Clinical Trial, and the Power of Family & Faith
“Clinical trials allow you to take advantage of the latest research and experiences from doctors and patients who’re blazing the trails. Clinical trials are also a way for you to help the next person who is going to have to go through this. If you have the opportunity to be part of something that helps others, why wouldn’t you at least try it?”
Melanoma Research Advances – 2019 in Review
During 2019, melanoma research continued its rapid pace of advancement, with FDA approval of a new adjuvant therapy treatment option, several first-in-human clinical trials, and significant progress towards earlier intervention.
2020 Melanoma Mortality Rates Decreasing Despite Ongoing Increase in Incidence
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for...
Doubling Down on Rare Melanomas
16 December 2019 In Science
Acral, uveal, and mucosal melanoma – known collectively as ‘rare melanomas’ – represent a type of black hole for the clinical community. We know far less about them—what causes them, how they progress, and how to effectively treat them.
Approaches to Neoadjuvant Treatment in Melanoma: A Public Workshop Organized by the FDA and MRA
On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.